Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study

• Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. • Baricitinb reduces SARS-CoV-2 viral burden detected by na...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantini, Fabrizio, Niccoli, Laura, Nannini, Carlotta, Matarrese, Daniela, Natale, Massimo Edoardo Di, Lotti, Pamela, Aquilini, Donatella, Landini, Giancarlo, Cimolato, Barbara, Pietro, Massimo Antonio Di, Trezzi, Michele, Stobbione, Paolo, Frausini, Gabriele, Navarra, Assunta, Nicastri, Emanuele, Sotgiu, Giovanni, Goletti, Delia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Infection Association. Published by Elsevier Ltd. 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313480/
https://www.ncbi.nlm.nih.gov/pubmed/32592703
http://dx.doi.org/10.1016/j.jinf.2020.06.052
_version_ 1783549946306232320
author Cantini, Fabrizio
Niccoli, Laura
Nannini, Carlotta
Matarrese, Daniela
Natale, Massimo Edoardo Di
Lotti, Pamela
Aquilini, Donatella
Landini, Giancarlo
Cimolato, Barbara
Pietro, Massimo Antonio Di
Trezzi, Michele
Stobbione, Paolo
Frausini, Gabriele
Navarra, Assunta
Nicastri, Emanuele
Sotgiu, Giovanni
Goletti, Delia
author_facet Cantini, Fabrizio
Niccoli, Laura
Nannini, Carlotta
Matarrese, Daniela
Natale, Massimo Edoardo Di
Lotti, Pamela
Aquilini, Donatella
Landini, Giancarlo
Cimolato, Barbara
Pietro, Massimo Antonio Di
Trezzi, Michele
Stobbione, Paolo
Frausini, Gabriele
Navarra, Assunta
Nicastri, Emanuele
Sotgiu, Giovanni
Goletti, Delia
author_sort Cantini, Fabrizio
collection PubMed
description • Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. • Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab. • Baricitinib used for 2 weeks was not associated with serious adverse events.
format Online
Article
Text
id pubmed-7313480
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The British Infection Association. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73134802020-06-24 Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study Cantini, Fabrizio Niccoli, Laura Nannini, Carlotta Matarrese, Daniela Natale, Massimo Edoardo Di Lotti, Pamela Aquilini, Donatella Landini, Giancarlo Cimolato, Barbara Pietro, Massimo Antonio Di Trezzi, Michele Stobbione, Paolo Frausini, Gabriele Navarra, Assunta Nicastri, Emanuele Sotgiu, Giovanni Goletti, Delia J Infect Letter to the Editor • Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry. • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate. • Baricitinib reduces intensive care unit admissions of COVID-19 pneumonia. • Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab. • Baricitinib used for 2 weeks was not associated with serious adverse events. The British Infection Association. Published by Elsevier Ltd. 2020-10 2020-06-24 /pmc/articles/PMC7313480/ /pubmed/32592703 http://dx.doi.org/10.1016/j.jinf.2020.06.052 Text en © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Cantini, Fabrizio
Niccoli, Laura
Nannini, Carlotta
Matarrese, Daniela
Natale, Massimo Edoardo Di
Lotti, Pamela
Aquilini, Donatella
Landini, Giancarlo
Cimolato, Barbara
Pietro, Massimo Antonio Di
Trezzi, Michele
Stobbione, Paolo
Frausini, Gabriele
Navarra, Assunta
Nicastri, Emanuele
Sotgiu, Giovanni
Goletti, Delia
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
title Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
title_full Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
title_fullStr Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
title_full_unstemmed Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
title_short Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
title_sort beneficial impact of baricitinib in covid-19 moderate pneumonia; multicentre study
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313480/
https://www.ncbi.nlm.nih.gov/pubmed/32592703
http://dx.doi.org/10.1016/j.jinf.2020.06.052
work_keys_str_mv AT cantinifabrizio beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT niccolilaura beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT nanninicarlotta beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT matarresedaniela beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT natalemassimoedoardodi beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT lottipamela beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT aquilinidonatella beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT landinigiancarlo beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT cimolatobarbara beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT pietromassimoantoniodi beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT trezzimichele beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT stobbionepaolo beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT frausinigabriele beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT navarraassunta beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT nicastriemanuele beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT sotgiugiovanni beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy
AT golettidelia beneficialimpactofbaricitinibincovid19moderatepneumoniamulticentrestudy

Ejemplares similares